SGMO · Sangamo Therapeutics, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.44M | - | $581.0K | $18.31M | $6.44M | - | $49.41M | $356.0K | $481.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $26.57M | - | $28.14M | $27.08M | $26.01M | - | $27.73M | $24.22M | $35.89M | - |
| SG&A | $6.82M | - | $7.99M | $9.08M | $10.06M | - | $11.05M | $12.04M | $11.77M | - |
| Total Operating Expenses | $33.39M | - | $36.13M | $36.16M | $36.06M | - | $38.78M | $37.44M | $52.01M | - |
| D&A | $719.0K | - | - | - | $1.02M | - | - | - | $1.41M | - |
| Operating Income | ($31.95M) | - | ($35.55M) | ($17.86M) | ($29.63M) | - | $10.63M | ($37.08M) | ($51.53M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | ($161.0K) | $27.0K | $119.0K | - | $88.0K | $74.0K | $98.0K | - |
| Net Income | ($31.00M) | - | ($34.93M) | ($19.99M) | ($30.60M) | - | $10.67M | ($36.13M) | ($49.09M) | - |
| EPS - Basic | ($0.08) | - | ($0.11) | ($0.08) | ($0.14) | - | $0.05 | ($0.18) | ($0.27) | - |
| EPS - Diluted | ($0.08) | - | ($0.11) | ($0.08) | ($0.14) | - | $0.04 | ($0.18) | ($0.27) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.59M | $20.95M | $29.62M | $38.34M | $25.18M | $41.92M | $39.20M | $27.79M | $54.42M | $45.20M |
| Accounts Receivable | $873.0K | $371.0K | $523.0K | $372.0K | $366.0K | $526.0K | $10.50M | $581.0K | $691.0K | $923.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $19.31M | $14.44M | $15.56M | $10.74M | $18.20M | $15.48M | $19.79M | $17.59M | $15.47M | $15.26M |
| Current Assets | $37.11M | $35.83M | $44.08M | $49.89M | $37.60M | $51.69M | $58.13M | $40.08M | $68.64M | $94.33M |
| Total Assets | $59.97M | $59.74M | $88.64M | $97.56M | $86.17M | $101.64M | $111.26M | $93.01M | $128.96M | $165.32M |
| Current Liabilities | $53.13M | $42.47M | $50.13M | $47.66M | $49.56M | $45.80M | $43.16M | $39.01M | $40.24M | $47.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $78.92M | $74.01M | $82.40M | $77.96M | $81.26M | $78.86M | $72.13M | $69.32M | $72.26M | $82.43M |
| Stockholders' Equity | ($18.95M) | ($14.27M) | $6.24M | $19.60M | $4.91M | $22.77M | $39.13M | $23.69M | $56.70M | $82.89M |
| Retained Earnings | ($1.66B) | ($1.63B) | ($1.59B) | ($1.55B) | ($1.53B) | ($1.50B) | ($1.48B) | ($1.49B) | ($1.46B) | ($1.41B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($19.28M) | - | - | - | ($26.15M) | - | - | - | ($48.66M) | - |
| Investing Cash Flow | ($13.0K) | - | - | - | $0 | - | - | - | $35.84M | - |
| Financing Cash Flow | $26.70M | - | - | - | $8.13M | - | - | - | $22.12M | - |
| CapEx | $13.0K | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | ($19.30M) | - | - | - | - | - | - | - | ($48.66M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -2215.4% | - | -6119.3% | -97.5% | -460.3% | - | 21.5% | -10416.9% | -10712.3% | - |
| EBITDA margin | -2165.5% | - | - | - | -444.4% | - | - | - | -10420.0% | - |
| Net margin | -2149.4% | - | -6012.0% | -109.2% | -475.3% | - | 21.6% | -10148.3% | -10205.6% | - |
| Free cash flow margin | -1338.1% | - | - | - | - | - | - | - | -10117.0% | - |
| FCF / Net income | 0.62 | - | - | - | - | - | - | - | 0.99 | - |
| R&D / Revenue | 1842.6% | - | 4843.7% | 148.0% | 404.0% | - | 56.1% | 6804.2% | 7461.7% | - |
| SG&A / Revenue | 472.8% | - | 1375.6% | 49.6% | 156.3% | - | 22.4% | 3383.4% | 2446.4% | - |
| Effective tax rate | - | - | - | - | - | - | 0.8% | - | - | - |
| Return on assets | -51.7% | - | -39.4% | -20.5% | -35.5% | - | 9.6% | -38.8% | -38.1% | - |
| Return on equity | 163.5% | - | -559.5% | -102.0% | -623.7% | - | 27.3% | -152.5% | -86.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.70 | 0.84 | 0.88 | 1.05 | 0.76 | 1.13 | 1.35 | 1.03 | 1.71 | 1.98 |
| Quick ratio | 0.70 | 0.84 | 0.88 | 1.05 | 0.76 | 1.13 | 1.35 | 1.03 | 1.71 | 1.98 |
| Cash ratio | 0.52 | 0.49 | 0.59 | 0.80 | 0.51 | 0.92 | 0.91 | 0.71 | 1.35 | 0.95 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -3.16 | -4.19 | 14.20 | 4.98 | 17.56 | 4.46 | 2.84 | 3.93 | 2.27 | 1.99 |
| Liabilities / Assets | 1.32 | 1.24 | 0.93 | 0.80 | 0.94 | 0.78 | 0.65 | 0.75 | 0.56 | 0.50 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.01 | 0.19 | 0.07 | - | 0.44 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 221d | - | 329d | 7d | 21d | - | 78d | 596d | 524d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | 21.8x | - | - | - |
| P / B | - | - | 32.7x | 7.1x | 29.6x | - | 4.8x | 3.1x | 2.1x | - |
| P / S | 67.5x | - | 350.9x | 7.6x | 22.6x | - | 3.8x | 206.2x | 251.2x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -77.6% | - | -98.8% | 5042.1% | 1238.3% | - | 425.8% | -94.8% | -99.7% | - |
| Revenue CAGR (3y) | -79.1% | - | -72.0% | -14.6% | -38.9% | - | 20.0% | -76.6% | -73.6% | - |
| Revenue CAGR (5y) | -44.0% | - | -60.1% | -3.2% | -13.2% | - | 17.6% | -54.1% | -43.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -7.8% | - | - | 51.9% | 42.5% | - | - | 70.0% | - | - |
| Net income growth (YoY) | -1.3% | - | - | 44.7% | 37.7% | - | - | 16.3% | - | - |
| EPS growth (YoY) | 42.9% | - | - | 55.6% | 48.1% | - | - | 72.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 36.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -84.0% | -17.3% | -91.3% | -72.5% | -71.0% | -89.9% | -80.8% | -71.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$39.55M totalReportable Segment$39.55M · 100.0%
Product / service
$25.60M totalLicense$18.00M · 70.3%
Initial License$7.60M · 29.7%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing SANGAMO THERAPEUTICS against the 5 most active filers in the same SIC group.